Movement Alert｜CARsgen Therapeutics Rises 5.47% in Regular Trading, Biotech Sector Rally and Solid Tumor CAR-T Milestone Boost Sentiment

Market Focus05-29

On May 29, CARsgen Therapeutics-B (02171.HK) rose 5.47% in regular trading, trading at HK$17.93/share, with trading volume of HK$44.85 million. The stock rebounded sharply following a 5.2% decline on May 26 caused by a discounted share placement.

The rally comes amid broad strength in the Hong Kong-listed biotech sector and renewed investor focus on the company's solid tumor CAR-T pipeline. CARsgen's CT041 (Suruikiorloncel, targeting CLDN18.2) is the world's first solid tumor CAR-T product to enter the NDA stage, with potential approval expected in the first half of this year — a milestone event for global cell therapy. The company's CAR-T gastric cancer therapy was also recently proposed for priority review designation, reinforcing the near-term commercial catalyst.

Within the Biotechnology sector, multiple peers posted significant gains. Among individual stocks, Innovent Biologics up 9.95%, Akeso up 5.43%, 3SBio up 4.64%, RemeGen up 1.58%, BeiGene up 0.74%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161071654?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 13:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161071654","market":"us","top_or_hot":-1,"title":"Movement Alert｜CARsgen Therapeutics Rises 5.47% in Regular Trading, Biotech Sector Rally and Solid Tumor CAR-T Milestone Boost Sentiment","media":"Market Focus","content":"<p><p>On May 29, CARsgen Therapeutics-B (02171.HK) rose 5.47% in regular trading, trading at HK$17.93/share, with trading volume of HK$44.85 million. The stock rebounded sharply following a 5.2% decline on May 26 caused by a discounted share placement.</p><p>The rally comes amid broad strength in the Hong Kong-listed biotech sector and renewed investor focus on the company's solid tumor CAR-T pipeline. CARsgen's CT041 (Suruikiorloncel, targeting CLDN18.2) is the world's first solid tumor CAR-T product to enter the NDA stage, with potential approval expected in the first half of this year — a milestone event for global cell therapy. The company's CAR-T gastric cancer therapy was also recently proposed for priority review designation, reinforcing the near-term commercial catalyst.</p><p>Within the Biotechnology sector, multiple peers posted significant gains. Among individual stocks, Innovent Biologics up 9.95%, Akeso up 5.43%, 3SBio up 4.64%, RemeGen up 1.58%, BeiGene up 0.74%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CARsgen Therapeutics Rises 5.47% in Regular Trading, Biotech Sector Rally and Solid Tumor CAR-T Milestone Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CARsgen Therapeutics Rises 5.47% in Regular Trading, Biotech Sector Rally and Solid Tumor CAR-T Milestone Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-29 13:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 29, CARsgen Therapeutics-B (02171.HK) rose 5.47% in regular trading, trading at HK$17.93/share, with trading volume of HK$44.85 million. The stock rebounded sharply following a 5.2% decline on May 26 caused by a discounted share placement.</p><p>The rally comes amid broad strength in the Hong Kong-listed biotech sector and renewed investor focus on the company's solid tumor CAR-T pipeline. CARsgen's CT041 (Suruikiorloncel, targeting CLDN18.2) is the world's first solid tumor CAR-T product to enter the NDA stage, with potential approval expected in the first half of this year — a milestone event for global cell therapy. The company's CAR-T gastric cancer therapy was also recently proposed for priority review designation, reinforcing the near-term commercial catalyst.</p><p>Within the Biotechnology sector, multiple peers posted significant gains. Among individual stocks, Innovent Biologics up 9.95%, Akeso up 5.43%, 3SBio up 4.64%, RemeGen up 1.58%, BeiGene up 0.74%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1161071654","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161071654","pubTimestamp":1780031586,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 29, CARsgen Therapeutics-B (02171.HK) rose 5.47% in regular trading, trading at HK$17.93/share, with trading volume of HK$44.85 million. The stock rebounded sharply following a 5.2% decline on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"动向提示|科济生物常规交易涨5.47%生物科技板块涨势实体瘤CAR-T里程碑提振人气","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"On May 29, CARsgen Therapeutics-B (02171.HK) rose 5.47% in regular trading, trading at HK$17.93/share, with trading volume of HK$44.85 million. The stock rebounded sharply following a 5.2% decline on May 26 caused by a discounted share placement.The rally comes amid broad strength in the Hong Kong-listed biotech sector and renewed investor focus on the company's solid tumor CAR-T pipeline. CARsgen's CT041 (Suruikiorloncel, targeting CLDN18.2) is the world's first solid tumor CAR-T product to enter the NDA stage, with potential approval expected in the first half of this year — a milestone event for global cell therapy. The company's CAR-T gastric cancer therapy was also recently proposed for priority review designation, reinforcing the near-term commercial catalyst.Within the Biotechnology sector, multiple peers posted significant gains. Among individual stocks, Innovent Biologics up 9.95%, Akeso up 5.43%, 3SBio up 4.64%, RemeGen up 1.58%, BeiGene up 0.74%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161071654","isCrawlerRequest":true}